ロード中...
The Androgen Receptor is a negative regulator of eIF4E Phosphorylation at S209: Implications for the use of mTOR inhibitors in advanced prostate cancer
The anti-androgen bicalutamide is widely used in the treatment of advanced prostate cancer (PCa) in many countries, but its effect on castration resistant PCa (CRPC) is limited. We previously showed that resistance to bicalutamide results from activation of mechanistic target of rapamycin (mTOR). In...
保存先:
| 出版年: | Oncogene |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5690844/ https://ncbi.nlm.nih.gov/pubmed/28745319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2017.233 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|